MGMT and cancer: Currently, the treatment of some cancers starts with an alkylating agent to induce DNA methylation at guanine (O6MeG), especially Temozolomide, and the combination with Lomeguatrib (an MGMT inhibitor) results in more cancer cell death, taking advantage of the high mutagenicity of O6MeG [95].